Jim Cramer sends strong 5-word message on surging biotech stock

On September 3, 2026, during an episode of CNBC's Mad Money, Jim Cramer delivered a succinct warning about Nuvation Bio (NUVB) stock. In just five words, the outspoken CNBC host declared, "This is a pure spec." Cramer's warning came as the stock price soared, driven by real news rather than speculation. The biopharma company's stock had climbed due to positive developments, but Cramer cautioned that the company's stock was highly volatile and speculative in nature.

Nuvation Bio, an early-stage oncology company, has one approved drug on the market and relies heavily on pipeline drugs in clinical trials. The company's stock value primarily rests on the success of these trials, rather than on steady profits. While the FDA has granted Fast Track Designation to one of Nuvation's experimental drugs for brain cancer, another drug already on the market has proven to be successful.

However, Wall Street analysts remain cautious, with the average 12-month price target for NUVB at $14.5, indicating a potential 113% upside from its recent price near $6.80.